soluprick sq bjørk 10 hep
alk-abelló as - allergen av hengebjørk - oppløsning til prikktest - 10 hep
soluprick sq derma pteronyssinus 10 hep
alk-abelló as - allergen av husstøvmidd, dermatophagoides pteronyssinus - oppløsning til prikktest - 10 hep
soluprick sq timotei 10 hep
alk-abelló as - allergen av phleum pratense - oppløsning til prikktest - 10 hep
alutard sq bjørk 100000 sq-e/ ml
2care4 aps - allergen av bjørkepollen - injeksjonsvæske, suspensjon - 100000 sq-e/ ml
acarizax 12 sq-hdm / 12 sq-hdm
alk-abelló as - allergen av husstøvmidd, dermatophagoides pteronyssinus / allergen av husstøvmidd, dermatophagoides farinae - sublingvalt lyofilisat - 12 sq-hdm / 12 sq-hdm
itulazax 12 sq-bet
alk-abelló as - allergen av bjørkepollen - sublingvalt lyofilisat - 12 sq-bet
itulazax 12 sq-bet
2care4 aps - allergen av bjørkepollen - smeltetablett - 12 sq-bet
alutard sq vepsegift 100000 sq-e/ ml
2care4 aps - allergen av vepsegift - injeksjonsvæske, suspensjon - 100000 sq-e/ ml
serenade aso
bayer ag - serenade aso inneholder mikroorganismen bacillus amyloliquefaciens (tidligere subtilis) (basert på naturlig forekommende bacillus amyloliquefaciens qst 713) og er klassifisert under frac kode 44.
blincyto
amgen europe b.v. - blinatumomab - forløpercellelymfoblastisk leukemi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.